Kevin A Schulman

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003
    Michaela A Dinan
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Clin Oncol 30:2725-30. 2012
  2. pmc Economic implications of potential changes to regulatory and reimbursement policies for medical devices
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 23:50-6. 2008
  3. pmc Parents' reported preference scores for childhood atopic dermatitis disease states
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    BMC Pediatr 4:21. 2004
  4. pmc Sensitivity of International Classification of Diseases codes for hyponatremia among commercially insured outpatients in the United States
    Alisa M Shea
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Nephrol 9:5. 2008
  5. ncbi request reprint A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors
    Kevin A Schulman
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC, USA
    N Engl J Med 347:1335-41. 2002
  6. pmc Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care
    Liana D Castel
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715 USA
    BMC Health Serv Res 3:1. 2003
  7. doi request reprint A policy approach to the development of molecular diagnostic tests
    Kevin A Schulman
    Duke Clinical Research Institute, Duke University School of Medicine and the Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Nat Biotechnol 28:1157-9. 2010
  8. ncbi request reprint Outcomes research in oncology: improving patients' experiences with cancer treatment
    Kevin A Schulman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Clin Ther 25:665-70. 2003
  9. pmc Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research
    Alice K Fortune-Greeley
    Center for Clinical and Genetic Economics, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 3:151-8. 2010
  10. ncbi request reprint Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis
    John J Engemann
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Infect Control Hosp Epidemiol 26:534-9. 2005

Research Grants

  1. ACTION EQOL STUDY
    Kevin Schulman; Fiscal Year: 2007

Detail Information

Publications124 found, 100 shown here

  1. doi request reprint Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003
    Michaela A Dinan
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Clin Oncol 30:2725-30. 2012
    ..However, this association may be confounded by PET-induced stage migration and selection bias. We examined the association between PET use and overall survival among Medicare beneficiaries with NSCLC...
  2. pmc Economic implications of potential changes to regulatory and reimbursement policies for medical devices
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 23:50-6. 2008
    ..To evaluate the impact of regulatory scenarios on the financial viability of medical device companies...
  3. pmc Parents' reported preference scores for childhood atopic dermatitis disease states
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    BMC Pediatr 4:21. 2004
    ....
  4. pmc Sensitivity of International Classification of Diseases codes for hyponatremia among commercially insured outpatients in the United States
    Alisa M Shea
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Nephrol 9:5. 2008
    ....
  5. ncbi request reprint A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors
    Kevin A Schulman
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC, USA
    N Engl J Med 347:1335-41. 2002
    ..It is unclear whether research conducted at academic institutions adheres to these new standards...
  6. pmc Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care
    Liana D Castel
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715 USA
    BMC Health Serv Res 3:1. 2003
    ..Our goal was to assess the effect of PRWORA on hospital uncompensated care in the United States...
  7. doi request reprint A policy approach to the development of molecular diagnostic tests
    Kevin A Schulman
    Duke Clinical Research Institute, Duke University School of Medicine and the Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, North Carolina, USA
    Nat Biotechnol 28:1157-9. 2010
    ..A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests...
  8. ncbi request reprint Outcomes research in oncology: improving patients' experiences with cancer treatment
    Kevin A Schulman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Clin Ther 25:665-70. 2003
    ..In doing so, we introduce the articles in this supplemental section, which address some of the unique concerns of outcomes researchers and outline the most important challenges confronting this research community...
  9. pmc Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research
    Alice K Fortune-Greeley
    Center for Clinical and Genetic Economics, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 3:151-8. 2010
    ..We examined the relationship between patients' reactions to standard informed consent language and their willingness to participate in a hypothetical clinical trial...
  10. ncbi request reprint Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis
    John J Engemann
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Infect Control Hosp Epidemiol 26:534-9. 2005
    ..To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients...
  11. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI...
  12. pmc Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients
    Yanhong Li
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Clin J Am Soc Nephrol 4:428-34. 2009
    ..Staphylococcus aureus is a leading cause of infection in patients with ESRD. Clinical and economic outcomes associated with S. aureus bacteremia and other S. aureus infections in patients with ESRD were examined...
  13. pmc Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial
    Kathryn E Flynn
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    JAMA 301:1451-9. 2009
    ..Findings from previous studies of the effects of exercise training on patient-reported health status have been inconsistent...
  14. doi request reprint Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction
    Seth W Glickman
    Center for Clinical and Genetic Economics, Duke University, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 3:188-95. 2010
    ..The objective of this study was to determine whether patient satisfaction is associated with adherence to practice guidelines and outcomes for acute myocardial infarction and to identify the key drivers of patient satisfaction...
  15. pmc Outcomes, health policy, and managed care: relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure
    Kathryn E Flynn
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Am Heart J 158:S64-71. 2009
    ..We examined associations between patient-reported measures of health-related quality of life and clinical indicators of disease severity in a large, heterogeneous sample of patients with heart failure...
  16. doi request reprint Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy
    Alisa M Shea
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 300:189-96. 2008
    ..Anecdotal reports suggest that these adjustments may have negatively affected access to chemotherapy for Medicare beneficiaries...
  17. ncbi request reprint Alternative pay-for-performance scoring methods: implications for quality improvement and patient outcomes
    Seth W Glickman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Med Care 47:1062-8. 2009
    ..Alternative methods that weight process measures according to how hospitals organize care and the range for possible improvement may be more closely related to patient outcomes...
  18. ncbi request reprint Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 152:500-8. 2006
    ..By examining this international trial population of high-risk patients, we sought to determine geographic variations in the use of 3 key treatments for MI...
  19. pmc Relationships between emerging measures of heart failure processes of care and clinical outcomes
    Adrian F Hernandez
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Am Heart J 159:406-13. 2010
    ..Previous studies have not confirmed associations between some current performance measures for inpatient heart failure processes of care and postdischarge outcomes. It is unknown if alternative measures are associated with outcomes...
  20. ncbi request reprint Perceived racial/ethnic bias in healthcare in Durham County, North Carolina: a comparison of community and national samples
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N C Med J 66:267-75. 2005
    ..We sought to compare findings of a national survey of perceptions of racial/ethnic discrimination in healthcare to those of a community survey, with emphasis on the perceptions of Latinos...
  21. doi request reprint Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007
    Kathleen T Unroe
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 171:196-203. 2011
    ..Heart failure is a common cause of death among Medicare beneficiaries, but little is known about health care resource use at the end of life...
  22. ncbi request reprint A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelin
    Seth W Glickman
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC, USA
    Am Heart J 154:1206-20. 2007
    ....
  23. ncbi request reprint Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 101:2574-83. 2004
    ..In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients...
  24. pmc In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial)
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Am J Cardiol 110:1150-5. 2012
    ..In conclusion, resource use and associated medical costs in the last year of life differed markedly in patients with HF who experienced SCD and patients who died of other causes...
  25. pmc Racial differences in health concern
    Corrine I Voils
    Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, 508 Fulton St, Durham, NC 27705, USA
    J Natl Med Assoc 98:36-42. 2006
    ..Interventions to inform blacks and Latinos about their health risks must strike a balance between creating enough health concern to encourage health behavior but not so much that it interferes with health-promoting behaviors...
  26. pmc Comparison of conflict of interest policies and reported practices in academic medical centers in the United States
    Michaela A Dinan
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Account Res 13:325-42. 2006
    ..Considerable differences in understanding of conflict of interest policies were observed between IRB and COIC officials...
  27. ncbi request reprint Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina Department of Medicine, Duke University School of Medicine, Durham, North Carolina Electronic address
    J Card Fail 19:611-20. 2013
    ..We compared medical resource use, costs, and health utilities between the treatment groups...
  28. ncbi request reprint Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia
    Jula K Inrig
    Department of Medicine, Division of Nephrology, Duke University Medical Center, Durham, NC 27705, USA
    Clin J Am Soc Nephrol 1:518-24. 2006
    ..Twelve-week mortality and costs that are associated with an episode of SAB are high in hemodialysis patients, regardless of vascular access type. Efforts should focus on the prevention of SAB in this high-risk group...
  29. ncbi request reprint Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Pharmacoeconomics 24:479-94. 2006
    ..We sought to compare resource use, costs and clinical outcomes between treatment groups and report the results using a cost-consequences framework...
  30. doi request reprint Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007
    Michaela A Dinan
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Radiology 267:807-17. 2013
    ..To explore demographic and regional factors associated with the use of positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) and to determine whether their associations with PET use has changed over time...
  31. ncbi request reprint Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study
    Lawrence Liao
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 153:245-52. 2007
    ..In a prospective, longitudinal cohort of community-dwelling elderly from 4 regions, we examined the long-term costs and resource use of elderly patients with HF...
  32. pmc Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries
    Adrian F Hernandez
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 300:2398-406. 2008
    ..In 2003, Medicare expanded coverage of ventricular assist devices as destination, or permanent, therapy for end-stage heart failure. Little is known about the long-term outcomes and costs associated with these devices...
  33. ncbi request reprint Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes
    Vivian H Chu
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 118:1416. 2005
    ..aureus bacteremia on patients with prosthetic devices. This investigation sought to define the clinical outcome, health care resource use, and infection-associated costs of S. aureus bacteremia in patients with prostheses...
  34. pmc Perceived discrimination and reported delay of pharmacy prescriptions and medical tests
    Courtney Harold Van Houtven
    Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, NC 27705, USA
    J Gen Intern Med 20:578-83. 2005
    ..Access to health care varies according to a person's race and ethnicity. Delaying treatment is one measure of access with important health consequences...
  35. doi request reprint Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database
    John L Petersen
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Am Heart J 159:462-470.e1. 2010
    ..Relationships between long-term use and level of dual antiplatelet therapy and outcomes after drug-eluting stent implantation are not well established...
  36. ncbi request reprint Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study
    Truls Østbye
    Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Pharmacoepidemiol Drug Saf 14:407-15. 2005
    ..We sought to compare the incidence of new onset diabetes among patients receiving atypical antipsychotics, traditional antipsychotics or antidepressants...
  37. doi request reprint Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries
    Lesley H Curtis
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Am J Ophthalmol 153:1116-24.e1. 2012
    ..To examine trends in the treatment of newly diagnosed neovascular age-related macular degeneration (AMD)...
  38. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
    ..We examined factors that influence the participation of gastroenterologists and hepatologists in clinical research...
  39. pmc Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents
    Kevin P Weinfurt
    Duke Clinical Research Institute, Duke Translational Medicine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 3:e2128. 2008
    ..We examined whether authors' financial interests were disclosed consistently in articles on coronary stents published in 2006...
  40. ncbi request reprint Outcomes of second revascularization procedures after stent implantation
    Richard P Konstance
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    J Med Syst 32:177-86. 2008
    ..Further studies are needed to determine the optimum application for CABG vs. DES as a second or third revascularization procedure...
  41. ncbi request reprint Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Arch Pediatr Adolesc Med 159:362-6. 2005
    ..Use of atypical antipsychotic medications in pediatric populations is increasing. Although previous studies have presented data by age or sex, none has documented sex-specific prevalence by age group...
  42. ncbi request reprint Geographic variation in carotid revascularization among Medicare beneficiaries, 2003-2006
    Manesh R Patel
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 170:1218-25. 2010
    ..We examined geographic variation in and predictors of carotid endarterectomy and carotid stenting...
  43. pmc Resource use and costs associated with diabetic macular edema in elderly persons
    Alisa M Shea
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Ophthalmol 126:1748-54. 2008
    ..To examine trends in resource use and the effect of incident diabetic macular edema (DME) on 1- and 3-year total direct medical costs in elderly patients...
  44. ncbi request reprint Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Clin Oncol 28:8-16. 2005
    ..There were no significant cost differences between patients receiving zoledronic acid and those receiving pamidronate...
  45. pmc Process of care performance measures and long-term outcomes in patients hospitalized with heart failure
    Mark E Patterson
    Center for Clinical and Genetic Economics, Duke University School of Medicine, Durham, NC, USA
    Med Care 48:210-6. 2010
    ..Recent efforts to improve care for patients hospitalized with heart failure have focused on process-based performance measures. Data supporting the link between current process measures and patient outcomes are sparse...
  46. pmc Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004
    David J Whellan
    Center for Clinical and Genetic Economics, Duke University School of Medicine, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 3:33-40. 2010
    ..Inpatient care is the primary driver of costs for patients with heart failure. It is unclear whether recent advances in heart failure care have reduced the costs to Medicare for the care of inpatients with heart failure...
  47. ncbi request reprint Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction
    Trip J Meine
    Duke University Medical Center, Durham, North Carolina, USA
    Ann Intern Med 143:481-5. 2005
    ....
  48. doi request reprint Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure
    Adrian F Hernandez
    Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC, USA
    Circ Heart Fail 3:7-13. 2010
    ..The clinical effectiveness of implantable cardioverter-defibrillators (ICDs) in older patients with heart failure has not been established, and older patients have been underrepresented in previous studies...
  49. doi request reprint Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008
    Laura G Qualls
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Retina 33:854-61. 2013
    ..To examine associations between newly diagnosed neovascular age-related macular degeneration and direct medical costs...
  50. pmc Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715, USA
    Acad Med 81:113-8. 2006
    ....
  51. pmc Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries
    Bradley G Hammill
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Circulation 121:63-70. 2010
    ..The relationship between the number of sessions attended and long-term outcomes is unknown...
  52. ncbi request reprint Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Curr Med Res Opin 24:41-50. 2008
    ..To explore relationships between beta-cell function and incident cardiovascular events, death, and medical costs among elderly individuals...
  53. doi request reprint Incidence and prevalence of heart failure in elderly persons, 1994-2003
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:418-24. 2008
    ..We sought to estimate the annual incidence and prevalence of heart failure and associated survival in elderly persons from January 1, 1994, through December 31, 2003...
  54. pmc Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial
    CHRISTOPHER M O'CONNOR
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 301:1439-50. 2009
    ..Guidelines recommend that exercise training be considered for medically stable outpatients with heart failure. Previous studies have not had adequate statistical power to measure the effects of exercise training on clinical outcomes...
  55. doi request reprint Perspective: The case for research justice: inclusion of patients with limited English proficiency in clinical research
    Seth W Glickman
    University of North Carolina, Chapel Hill, North Carolina, USA
    Acad Med 86:389-93. 2011
    ..LEP individuals should have fair access to clinical research in order to fully realize individual and societal benefits of their participation and to ensure the generalizability of scientific discovery...
  56. ncbi request reprint Costs of vasospasm in patients with aneurysmal subarachnoid hemorrhage
    Chia Hung Chou
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Neurosurgery 67:345-51; discussion 351-2. 2010
    ..To assess the impact of vasospasm on costs, length of stay, and mortality among inpatients with aneurysmal subarachnoid hemorrhage...
  57. pmc Effects of disclosing financial interests on participation in medical research: a randomized vignette trial
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Am Heart J 156:689-97. 2008
    ..Little is known about the effects of investigators' financial disclosures on potential research participants...
  58. pmc Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Tr
    Allen E Atchley
    Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 158:S53-63. 2009
    ..This article addresses the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) gated SPECT imaging (gSPECT) substudy baseline results...
  59. ncbi request reprint Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days
    William Boulding
    The Fuqua School of Business, Duke University, Durham, NC, USA
    Am J Manag Care 17:41-8. 2011
    ....
  60. ncbi request reprint Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Cancer 103:140-7. 2005
    ..The authors sought to characterize a special form of numeracy among patients with advanced cancer who were offered participation in Phase I oncology clinical trials...
  61. ncbi request reprint Costs for heart failure with normal vs reduced ejection fraction
    Lawrence Liao
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Arch Intern Med 166:112-8. 2006
    ..However, there are few data regarding the costs of HF with normal EF. In a prospective, population-based cohort of elderly participants, we compared the costs and resource use of patients with HF and normal and reduced EF...
  62. ncbi request reprint Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
    Venita Depuy
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Support Care Cancer 15:869-76. 2007
    ..We sought to quantify the longitudinal effects on patient-reported outcomes of skeletal-related events (SREs) and to ascertain the declines in health-related quality of life (HRQOL) and pain experienced by patients who experienced SREs...
  63. ncbi request reprint Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
    ..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
  64. pmc Economic return of clinical trials performed under the pediatric exclusivity program
    Jennifer S Li
    Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA
    JAMA 297:480-8. 2007
    ..This critique has been a substantial part of congressional debate on the program, which is due to expire in 2007...
  65. pmc N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 158:S37-44. 2009
    ..To examine the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and exercise capacity in a large contemporary cohort of patients with chronic heart failure...
  66. pmc Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    J Card Fail 18:784-91. 2012
    ..Reports that patients with heart failure and anemia incur greater costs and medical resource use have relied largely on data with limited clinical detail...
  67. ncbi request reprint The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?
    Joeëlle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Cancer 110:2304-12. 2007
    ....
  68. doi request reprint Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006
    Michaela A Dinan
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    JAMA 303:1625-31. 2010
    ..Imaging is the fastest growing expense for Medicare but has not been examined among beneficiaries with cancer...
  69. ncbi request reprint Inappropriate prescribing for elderly Americans in a large outpatient population
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 164:1621-5. 2004
    ..We sought to determine the extent of potentially inappropriate outpatient prescribing for elderly patients, as defined by the Beers revised list of drugs to be avoided in elderly populations...
  70. doi request reprint Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    Shelby D Reed
    Center for Clinical and Genetic Economics and Outcomes Research and Assessment Group, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Clin Oncol 27:2185-91. 2009
    ....
  71. pmc Developing model language for disclosing financial interests to potential clinical research participants
    Kevin P Weinfurt
    Duke University School of Medicine, Durham, NC, USA
    IRB 29:1-5. 2007
  72. doi request reprint Prostate-specific antigen screening among young men in the United States
    Charles D Scales
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Cancer 113:1315-23. 2008
    ..Little is known about the use of PSA testing in these men. To understand policy implications of risk stratification, the authors sought to characterize PSA use among young men...
  73. pmc External validity of the cardiovascular health study: a comparison with the Medicare population
    Lisa D DiMartino
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Med Care 47:916-23. 2009
    ..The Cardiovascular Health Study (CHS), a population-based prospective cohort study, has been used to identify major risk factors associated with cardiovascular disease and stroke in the elderly...
  74. ncbi request reprint Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Durham, NC, USA
    Am Heart J 148:122-8. 2004
    ..We sought to compare resource use, costs, and health outcomes among patients taking prescribed therapy for heart failure and randomly assigned to receive valsartan or placebo...
  75. pmc Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 25:460-4. 2010
    ..Studies of conflicts of interest in clinical research have focused on academic centers, but most clinical research takes place in nonacademic settings...
  76. pmc Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715, USA
    Health Serv Res 41:837-55. 2006
    ..To measure geographic variation in opioid use in a large, commercially insured, outpatient population in the United States...
  77. ncbi request reprint Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute
    Clin Trials 4:272-8. 2007
    ....
  78. pmc Linking inpatient clinical registry data to Medicare claims data using indirect identifiers
    Bradley G Hammill
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Am Heart J 157:995-1000. 2009
    ..We present a method to link hospitalization records from registries with Medicare inpatient claims data, without using direct identifiers, to create a unique data source that pairs rich clinical data with long-term outcome data...
  79. pmc Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures
    Michaela A Dinan
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Am J Hematol 84:703-9. 2009
    ..Patients with SCD who underwent cholecystectomy or hip replacement required more health care resources than patients without SCD. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  80. ncbi request reprint Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
    Shelby D Reed
    Center for Clinical and Genetic Economics, USA
    Infect Control Hosp Epidemiol 26:175-83. 2005
    ..We compared costs and outcomes of methicillin resistance in patients with S. aureus bacteremia and a single chronic condition...
  81. ncbi request reprint Exploring options for improving healthcare
    Stanley S Wang
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 147:23-30. 2004
    ....
  82. ncbi request reprint Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Kevin J Anstrom
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 101:2584-92. 2004
    ..The authors estimated survival among patients with chronic myeloid leukemia for a cost-effectiveness analysis of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC)...
  83. ncbi request reprint The insurance effect on prescription drug expenditures among the elderly: findings from the 1997 Medical Expenditure Panel Survey
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Med Care 42:439-46. 2004
    ..Despite continuing debate over a prescription drug benefit for the Medicare program, there has been relatively little research estimating the potential cost of providing such a benefit...
  84. ncbi request reprint Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey
    Amy W Law
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    J Allergy Clin Immunol 111:296-300. 2003
    ..Previous estimates of the cost of allergic rhinitis predate the substantial increase in the use of second-generation antihistamines and intranasal corticosteroids...
  85. ncbi request reprint Analytic considerations in economic evaluations of multinational cardiovascular clinical trials
    Frank M Torti
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Value Health 9:281-91. 2006
    ..Although recommendations for conducting economic evaluations have been widely disseminated, relatively little guidance has been given for conducting economic evaluations alongside clinical trials, particularly multinational trials...
  86. pmc Early and long-term outcomes of heart failure in elderly persons, 2001-2005
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:2481-8. 2008
    ..The treatment of chronic heart failure has improved during the past 2 decades, but little is known about whether the improvements are reflected in trends in early and long-term mortality and hospital readmission...
  87. ncbi request reprint The correlation between patient characteristics and expectations of benefit from Phase I clinical trials
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Cancer 98:166-75. 2003
    ..The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials...
  88. pmc Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Med Decis Making 28:575-81. 2008
    ..There is concern that participants misunderstand the trials to which they have consented, which is based on assumptions about what patients mean when responding to questions about likelihood of benefit...
  89. ncbi request reprint Variations in coronary procedure utilization depending on body mass index
    William S Yancy
    Center for Health Services Research in Primary Care, Veterans Affairs Medical Center, Durham, NC 27705, USA
    Arch Intern Med 165:1381-7. 2005
    ..The relationship between BMI and utilization of diagnostic or therapeutic procedures for coronary heart disease has not been examined...
  90. pmc Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005
    Sana M Al-Khatib
    Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Arrhythm Electrophysiol 1:240-9. 2008
    ..We examined patient and implanting physician factors associated with outcomes of ICD therapy in Medicare beneficiaries from 2002 through 2005...
  91. pmc Assessment of left ventricular function in older Medicare beneficiaries with newly diagnosed heart failure
    Lesley H Curtis
    Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:85-91. 2011
    ..Little is known about the extent to which left ventricular function is assessed in real-world settings...
  92. doi request reprint End point selection in acute decompensated heart failure clinical trials: economic end points
    Shelby D Reed
    Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Heart Fail Clin 7:529-37. 2011
    ..Integrating economic end points with concrete clinical outcomes postdischarge will provide meaningful data to evaluate a treatment's incremental value in the setting of ADHF...
  93. doi request reprint Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration
    Lesley H Curtis
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Arch Ophthalmol 128:1273-9. 2010
    ..To examine associations between therapies for age-related macular degeneration and risks of all-cause mortality, incident myocardial infarction, bleeding, and incident stroke...
  94. ncbi request reprint Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death
    Lesley H Curtis
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    JAMA 298:1517-24. 2007
    ..Previous studies of sex differences in the use of implantable cardioverter-defibrillators (ICDs) predate recent expansions in Medicare coverage and did not provide patient follow-up over multiple years...
  95. ncbi request reprint Perceptions of racial and ethnic differences in access to healthcare
    Damon M Seils
    Center for Clinical and Genetic Economics, Duke University, Durham, NC 27715, USA
    N C Med J 65:350-2. 2004
  96. ncbi request reprint Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center Durham, North Carolina, USA
    J Urol 171:1537-42. 2004
    ..We estimated the cost-effectiveness of zoledronic acid vs placebo for decreasing skeletal complications in men with prostate cancer...
  97. ncbi request reprint Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction
    Frank A Sloan
    Department of Economics, Duke University, Durham, North Carolina 27708, USA
    Med Care 41:1193-205. 2003
    ..Concerns have been expressed about quality of for-profit hospitals and their use of expensive technologies...
  98. ncbi request reprint The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction
    Frank A Sloan
    Department of Economics and Clinical Research Institute, Duke University, Durham, North Carolina 27708, USA
    J Am Geriatr Soc 52:173-81. 2004
    ..To determine differences in mortality after admission for acute myocardial infarction (AMI) and in use of noninvasive and invasive treatments for AMI between patients with and without dementia...
  99. pmc Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions
    Kathryn E Flynn
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Clin Trials 5:575-86. 2008
    ....
  100. pmc Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry
    Adrian F Hernandez
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Am Coll Cardiol 53:184-92. 2009
    ..We sought to examine associations between initiation of beta-blocker therapy and outcomes among elderly patients hospitalized for heart failure...
  101. doi request reprint Decision making and quality of life in the treatment of cancer: a review
    S Yousuf Zafar
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 17:117-27. 2009
    ..Although these factors are important, physicians are often unable to effectively judge their patients' preferences. Patients are often unable to fully understand their prognoses and the treatment intent...

Research Grants2

  1. ACTION EQOL STUDY
    Kevin Schulman; Fiscal Year: 2007
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..